Second- [24] and third-generation CARs [25] incorporate one or two additional intracellular costimulatory domains, respectively, such as CD28 or 4-1BB (CD137), enhancing NK cell effector functions such as cytokine production and target MM cell lysis. This evidence concerns the gene TNFRSF9 and Miyoshi myopathy.